ArticleScientific reports2025
Treatment of pseudophakic aqueous misdirection syndrome.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Phacoemulsification with goniosynechialysis for nanophthalmos with secondary angle-closure or secondary angle-closure glaucoma: a 20-case series and stepwise management strategy.BMC ophthalmology · 2026Article
- Malignant Glaucoma After Trabeculectomy-Diagnosis and Treatment Options: A Case Report.Reports (MDPI) · 2026Article
- Acute fluid misdirection syndrome in intraocular collamer lens implantation: a case report and review of literature.BMC ophthalmology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To describe the management and clinical course of 12 cases of pseudophakic aqueous misdirection syndrome (AMS). Twelve eyes of 12 Patients diagnosed with pseudophakic AMS between 2021 and 2022 were included. Best-corrected visual acuity, refraction, intraocular pressure (IOP), anti-glaucomatous medication, spectral domain ocular coherence tomography (SD-OCT) and postoperative complications were evaluated. The mean time of AMS onset was 888 days (SD ± 1210, range: 1-2920) after cataract surgery. Treatment with IOP-lowering medication alone was non-sufficient in all followed cases. Laser iridotomy (LIT) was performed in 4 eyes and led to resolution of AMS in 3 eyes. Nine eyes were treated surgically with 23-gauge pars plana vitrectomy and irido-zonulectomy. The most common postsurgical complication was cystoid macular edema (CME), occurring in 30% of cases. AMS is a rare but serious complication after cataract surgery, which can occur many years later. While LIT can be tried as first line treatment, pars plana vitrectomy with irido-zonulectomy is often required to ultimately control IOP in these eyes. A common complication after vitrectomy is CME.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.